Advances in acute myeloid leukemia (AML) treatment – updating 7+3
The epigenetics of multiple myeloma and the rationale for HDAC inhibitors
How can standard risk multiple myeloma (MM) patients be cured?
The impact of new drugs and the changing role of transplants in multiple myeloma
Multiple myeloma depth of response to therapy at different stages